Avanos Medical today announced it entered into a definitive agreement to acquire OrthogenRx for $160 million.
OrthogenRx currently makes viscosupplementation therapies to treat knee osteoarthritis pain, as well as its commercial hyaluronic acid (HA) therapy products GenVisc 850 and TriVisc. Avanos will purchase the company for $130 million in cash at closing and an additional $30 million in contingent cash consideration upon the achievement of growth milestones related to the HA therapy products.
Get the full story on our sister site, Drug Delivery Business News.